Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188968 | 0.88 | LMNA (0.53) | MAPTKMT2ALMNAMEN1AKR1C3 | |
| SCHEMBL145023 | 0.84 | MAPT (0.62) | MAPTKMT2ALMNAMEN1AKR1C3 | |
| SCHEMBL21672257 | 0.84 | MAPT (0.50) | MAPTKMT2ALMNAMEN1AKR1C3 | |
| SCHEMBL8233274 | 0.81 | MAPT (0.61) | MAPTKMT2ALMNAMEN1AKR1C3 | |
| SCHEMBL2335498 | 0.81 | GAA (0.57) | MAPTKMT2ALMNAMEN1HPGD | |
| SCHEMBL7153117 | 0.81 | MAPT (0.64) | MAPTKMT2ALMNAMEN1AKR1C3 | |
| SCHEMBL30441386 | 0.81 | MAPT (0.64) | MAPTKMT2ALMNAMEN1AKR1C3 | |
| SCHEMBL12374635 | 0.81 | LMNA (0.74) | MAPTKMT2ALMNAMEN1AKR1C3 | |
| SCHEMBL23675133 | 0.80 | MAPT (0.81) | MAPTKMT2ALMNAMEN1AKR1C3 | |
| SCHEMBL2367866 | 0.80 | MAPT (0.51) | MAPTKMT2ALMNAMEN1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102388035-A | Benzimidazole derivatives and their use for modulating the gabaa receptor complex | NEUROSEARCH AS | 2012-03-21 | — | — | CN | disclosed |
| US-20110257210-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2011-10-20 | — | — | US | disclosed |
| US-20110257210-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2011-10-20 | — | — | US | disclosed |
| EP-2358701-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NeuroSearch A/S (DK) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010055129-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055128-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055128-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055129-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257210-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | MAPT 4558/4885KMT2A 2883/4885LMNA 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.